Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T20:33:06.361Z.
Calculation as of: 2026-10-06T20:33:06.361Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad03cc2eaddb42082332b148aee8d6851fa015397d59a0785f41cacae5aa3ea4
PEG RATIO
N/A
Starling Oncology, Inc.
Market Cap
$657.89M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | N/A |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.95M | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | N/A |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
